# **Expanded CMV Newborn Screening: Adding Intrauterine Growth Restriction Diagnosis to Targeted CMV Screening in Newborns**

Karen B. Fowler, Suresh B. Boppana, Shannon A. Ross Division of Pediatric Infectious Diseases, UAB Heersink School of Medicine

Email: karenfowler@uabmc.edu



# Background

Intrauterine growth restriction (IUGR) has been observed in symptomatic congenital CMV infections (cCMV).

IUGR is considered a sign of cCMV when it occurs among a constellation of other CMV-related symptoms.

(Rawlinson WD, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis 2017. 17:e177-88)

It is unknown if IUGR alone could indicate cCMV.

Some targeted newborn cCMV screening programs are considering IUGR as part of an expanded cCMV screening approach.



# Objective

To determine the frequency of IUGR among infants screened for cCMV and whether IUGR could be used for an expanded cCMV screening approach.



## Methods

CHIMES Study – 12,192 UAB infants prospectively enrolled between 2007 & 2012.

- Saliva and DBS were collected from newborns and tested for CMV by PCR.
- Infants with positive screening specimens enrolled in follow-up to confirm cCMV.
- Maternal, demographic, limited EMR, & auditory information collected for the total cohort.

Maternal CMV seroprevalence was determined from stored DBS samples (n=10,106) for CMV IgG testing via an in-house CMV ELISA.

IUGR is defined as birth weight below the 10<sup>th</sup> percentile for gestational age and includes both asymmetric and symmetric IUGR.



#### **Study Characteristics (12,192)**

Race/Ethnicity		%
	Black, non-Hispanic	52.8
	White, non-Hispanic	22.3
	White, Hispanic	21.7
	Asian	1.0
	Multiracial	2.2
Insurance –Hospital Stay		%
	Medicaid/No Insurance	84.8
	Commercial	15.2



#### **Study Characteristics (12,192)**

Nursery	%	
NBN	85.1	
NICU	14.9	
Infant CMV status	per 1000	
Positive (n=98)	8	
IUGR	%	
IUGR/SGA	7.8	




#### **Study Characteristics (12,192)**

Maternal Age	Mean (SD)	
Age, years	25.1 (5.8)	
Gradivity	%	
Primigravida	30.3	
Maternal Seroprevalence*	%	
CMV Seropositive	56.1	
CMV Seronegative	43.4	
Unknown	0.5	

<sup>\*2,086</sup> either no stored card or not enough DBS sample to test





RR<sub>IUGR</sub>: 3.2 (95% CI, 2.2 – 4.5)



#### Other Maternal Factors and IUGR


	IUGR	No IUGR
Black, non-Hispanic*	67.3%	51.4%
Medicaid/No Insurance*	89.6%	84.4%
Primigravida*	37.7%	29.7%
Maternal Age, years*	$24.0 \pm 5.7$	25.1 ± 5.8
Maternal CMV Seropositivity	56.3%	56.0%

<sup>\*</sup>p < 0.0001

Adjusted RRiugr: 2.7 (95% CI, 1.9 – 3.8)


Adj for: Maternal age, parity, race/ethnicity, SES







\*Generalized petechial rash, purpuric rash, hepatomegaly, splenomegaly, jaundice with direct bilirubin of 3 mg/dL or greater, unexplained neurologic/CNS abnormalities (eg, microcephaly, seizures, focal or generalized neurologic deficits)



## Conclusions

- Infants with cCMV had a significant increased risk for IUGR compared to uninfected infants.
- About 25% of CMV-infected infants had IUGR.
- IUGR was identified in 19% of asymptomatic infants without any other physical findings.
- Expanding targeted screening to include IUGR will identify about 33% of cCMV infants and identify 86% of CMV-related hearing loss.
- Only universal cCMV screening will identify all infants with cCMV in the population.

# Acknowledgements

- CHIMES Study funded by the National Institute on Deafness and Other Communication Disorders (NIDCD) grants N01-DC-5-0008 and HHS-N-263-2012-00010-C
- Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) grant R03 HD101750
- Funded by Children's of Alabama Kaul Pediatric Research Institute grant







Prevent CMV



Remember not to put anything in your mouth that has recently been in a child's mouth.

Promoting Healthy Pregnancies for all women

